Sagimet Biosciences (SGMT) Company Overview

Profile

Full Name:

Sagimet Biosciences Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

July 17, 2023

Indexes:

Not included

Description:

Sagimet Biosciences focuses on developing innovative treatments for liver diseases. Their lead product, SGMT, targets non-alcoholic steatohepatitis (NASH), a serious liver condition. The company aims to improve patient outcomes through advanced therapies that address unmet medical needs in liver health.

Events Calendar

Earnings

Next earnings date:

Mar 25, 2025

Recent quarterly earnings:

Nov 14, 2024

Recent annual earnings:

Mar 25, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 27, 25 Jones Trading
Buy
Dec 6, 24 Oppenheimer
Outperform
Nov 15, 24 HC Wainwright & Co.
Buy
Nov 12, 24 UBS
Buy
Oct 31, 24 HC Wainwright & Co.
Buy
Oct 2, 24 HC Wainwright & Co.
Buy
Aug 15, 24 JMP Securities
Market Outperform
Aug 15, 24 HC Wainwright & Co.
Buy
Jul 1, 24 Goldman Sachs
Neutral
Jun 14, 24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

FAQ

  • What is the ticker symbol for Sagimet Biosciences?
  • Does Sagimet Biosciences pay dividends?
  • What sector is Sagimet Biosciences in?
  • What industry is Sagimet Biosciences in?
  • What country is Sagimet Biosciences based in?
  • When did Sagimet Biosciences go public?
  • Is Sagimet Biosciences in the S&P 500?
  • Is Sagimet Biosciences in the NASDAQ 100?
  • Is Sagimet Biosciences in the Dow Jones?
  • When was Sagimet Biosciences's last earnings report?
  • When does Sagimet Biosciences report earnings?
  • Should I buy Sagimet Biosciences stock now?

What is the ticker symbol for Sagimet Biosciences?

The ticker symbol for Sagimet Biosciences is NASDAQ:SGMT

Does Sagimet Biosciences pay dividends?

No, Sagimet Biosciences does not pay dividends

What sector is Sagimet Biosciences in?

Sagimet Biosciences is in the Healthcare sector

What industry is Sagimet Biosciences in?

Sagimet Biosciences is in the Biotechnology industry

What country is Sagimet Biosciences based in?

Sagimet Biosciences is headquartered in United States

When did Sagimet Biosciences go public?

Sagimet Biosciences's initial public offering (IPO) was on July 17, 2023

Is Sagimet Biosciences in the S&P 500?

No, Sagimet Biosciences is not included in the S&P 500 index

Is Sagimet Biosciences in the NASDAQ 100?

No, Sagimet Biosciences is not included in the NASDAQ 100 index

Is Sagimet Biosciences in the Dow Jones?

No, Sagimet Biosciences is not included in the Dow Jones index

When was Sagimet Biosciences's last earnings report?

Sagimet Biosciences's most recent earnings report was on Nov 14, 2024

When does Sagimet Biosciences report earnings?

The next expected earnings date for Sagimet Biosciences is Mar 25, 2025

Should I buy Sagimet Biosciences stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions